Actively Recruiting
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Led by C4 Therapeutics, Inc. · Updated on 2026-04-17
60
Participants Needed
16
Research Sites
173 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of the study will evaluate different dose levels of cemsidomide in combination with elranatamab in a limited number of subjects. Approximately 3 different dose levels of cemsidomide in combination with elranatamab may be explored. Once a dose level is determined safe, additional subjects may be enrolled through expansion of the dose level. This expansion will provide further exploration of the safety and evaluation of preliminary antimyeloma activity. Cemsidomide will be taken orally each cycle for 14 days on/14 days off (1 cycle=28 days). Elranatamab will be administered by subcutaneous injection twice a month. Dexamethasone will be administered weekly until a confirmed response but no longer than 4 cycles.
CONDITIONS
Official Title
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of multiple myeloma as defined by IMWG criteria
- Measurable disease based on IMWG criteria
- Received 2-4 prior lines of therapy (escalation part) or 1-3 prior lines of therapy (expansion part) including at least 1 immunomodulatory drug
- ECOG performance status of 0 to 2
You will not qualify if you...
- Active plasma cell leukemia, smoldering multiple myeloma, POEMS syndrome, systemic light chain amyloidosis, or myelodysplastic syndrome
- Stem cell transplant within 12 weeks before enrollment or active graft versus host disease
- Any active, uncontrolled bacterial, fungal, or viral infection
- Prior treatment with BCMA-directed T-cell engager or BCMA-directed CAR-T therapy
- Use of an investigational drug within 30 days before the first study dose
- Difficulty swallowing tablets, malabsorption syndrome, or significant gastrointestinal conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States, 85234
Not Yet Recruiting
2
UCLA Health, Jonsson Comprehensive Cancer Center
Santa Monica, California, United States, 90404
Not Yet Recruiting
3
Tampa General Hospital
Tampa, Florida, United States, 33606
Not Yet Recruiting
4
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States, 30322
Actively Recruiting
5
Loyola University Medical Center
Maywood, Illinois, United States, 60153
Not Yet Recruiting
6
Indiana University
Indianapolis, Indiana, United States, 46202
Not Yet Recruiting
7
Norton Cancer Institute St. Matthews
Louisville, Kentucky, United States, 40207
Not Yet Recruiting
8
University of Maryland Greenbaum Comprehensive Cancer Center
Baltimore, Maryland, United States, 21201
Not Yet Recruiting
9
START Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
10
University of Nebraska
Omaha, Nebraska, United States, 68105
Not Yet Recruiting
11
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Not Yet Recruiting
12
Perlmutter Cancer Center at NYU Langone Hospital
Brooklyn, New York, United States, 11203
Not Yet Recruiting
13
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021
Not Yet Recruiting
14
Duke Cancer Center
Durham, North Carolina, United States, 27710
Not Yet Recruiting
15
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Not Yet Recruiting
16
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States, 84112
Not Yet Recruiting
Research Team
S
Study Medical Officer
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here